Today: 2 July 2026
NGX Group share price holds at ₦122 as investors eye Feb 24 audited results meeting
21 February 2026
1 min read

NGX Group share price holds at ₦122 as investors eye Feb 24 audited results meeting

Lagos, Feb 21, 2026, 10:00 WAT — The market is now closed.

  • NGX Group ended Friday flat, with shares holding steady at ₦122.00.
  • A board meeting is set for Feb. 24, where the company will review its audited financials for 2025.
  • Exchange data showed the NGX All-Share Index climbed 6.95% for the week ending Feb. 20, with turnover sharply higher.

Shares of Nigerian Exchange Group Plc (NGXGROUP) closed flat at 122.00 naira on Friday, with traders eyeing a packed earnings schedule ahead—potentially the catalyst for the stock’s next move.

The exchange operator’s fortunes are tied closely to trading activity in Nigeria—fee income climbs as turnover picks up, and pulls back just as quickly when volumes drop off.

Nigerian Exchange (NGX) tracked a jump in weekly equity turnover, with 7.662 billion shares changing hands in 345,118 transactions, totaling 252.566 billion naira for the week ended Feb. 20. That’s a sizable pick-up from the previous week’s 4.652 billion shares and 193.326 billion naira. The NGX All-Share Index climbed 6.95% to 194,989.77, while market capitalisation reached 125.164 trillion naira, according to the weekly market report.

NGX Group announced its board plans to convene on Feb. 24 to review and sign off on audited results for the year ended Dec. 31, 2025. According to the company, the “closed period”—which blocks insider trading—won’t lift until a day after those audited accounts are officially filed and made public. Nigerian Stock Exchange

NGXGROUP finished Friday at 122.00 naira, with roughly 5.95 million shares swapping hands in 1,234 trades, according to the APT Securities daily price sheet.

Another thing on investors’ radar: the pace of fresh listings on the exchange. This week, Dangote Cement’s commercial paper joined the trading board — commercial paper refers to short-term corporate debt, typically sold below face value and paid back in full at maturity.

David Adonri, vice chairman at Highcap Securities, described the deal as “an important step” for Nigeria’s short-term debt market. He highlighted that investors are looking for stronger corporate paper. Channels Television

Even so, NGX Group’s fortunes hinge on sentiment. If equities retreat or daily turnover slumps, fee income takes an immediate knock. Delays tied to audited results or decisions on dividends? That could unsettle traders’ positions fast.

Once trading picks up, attention swings to Tuesday’s board meeting and, right after, the timing of the audited filing—both will dictate how fast investors shift from “earnings anticipation” to “earnings reaction.”

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Previous Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop